Comparative in vitro Dissolution and in vivo Bioequivalence of 2 Pentoxifylline Sustained Release Formulations

Tabriz University of Medical Sciences, Tabriz, Iran.
Arzneimittel-Forschung (Impact Factor: 0.7). 05/2012; 62(7):335-9. DOI: 10.1055/s-0032-1312600
Source: PubMed


Pentoxifylline is a xanthine derivative that is indicated for the treatment of patients with intermittent claudication on the basis of chronic occlusive arterial disease of the limbs. In the present study, prior to the in vivo study, an in vitro comparative dissolution test was performed by the paddle method for 2 oral sustained release pentoxifylline tablets (400 mg) following the bioequivalence guidance of FDA. Metrics of peak exposure (Cmax) and total exposure to 24 h (AUC24) were compared using a randomized, single oral, open-label, 2-period, 2-sequence, 2 treatments crossover study in 24 healthy male volunteers under fasted conditions. After an overnight fast, the volunteers received 400 mg pentoxifylline and the blood samples were collected over a 24-h period following drug administration. Plasma drug concentrations were measured by a reverse-phase HPLC method with ultraviolet detection. In vitro dissolution tests requirements were met by both formulations. Observed exposure metrics for test and reference products were 140.6±51.5 and 132.6±48.5 ng/ml for Cmax and 986.4±350.7 and 1 035.8±350.3 ng.h/ml for AUC0-24 respectively. The confidence intervals (90%) around ratios (test/reference) of least squares means derived from logarithmic transformed exposure metrics were 0.9912-1.1564% for Cmax and 0.8886-1.0535% for AUC0-24. Therefore it can be concluded that both products are bioequivalent in terms of peak and total exposure and therefore interchangeable.

Download full-text


Available from: Parvin Zakeri, Aug 06, 2015
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: In the present study pharmacokinetics and bioequivalence of 2 brands of ciprofloxacin 500 mg were evaluated in 24 healthy male volunteers after a single dose oral administration in an open, randomized, 2-way crossover study.Blood samples were taken before and within 12 h after the administration of the drug. Plasma concentrations of ciprofloxacin were determined by a simple HPLC method with ultraviolet detection. The used method was validated for specificity, accuracy, precision and sensitivity. The mobile phase consisted of 0.025 M phosphoric acid, acetonitrile, and triethylamine. Analytical column was 5 μm Eurosphere C8 with a Eurosphere C8 guard column. The detector wavelength was set at 278 nm and the retention time was 10 min. The pharmacokinetic parameters, including peak plasma concentrations and time needed to reach the peak were obtained directly from plasma concentration-time profiles. The area under the curve was calculated using non-compartmental methods.The Cmax of 1476.8±319.9 ng/mL and 1 423.0±278.4 ng/mL were attained in about 1.67 and 1.58 h for test and reference formulations, respectively. The mean±SD values for AUC0-∞ were 9 665.3±2 880.2 and 9 716.1±2 572.1 for test and reference formulations, respectively. The pharmacokinetics parameters AUC0-t, AUC0-∞ and Cmax were calculated for bioequivalence after log-transformation of data. The 90% confidence intervals of test/reference for AUC0-t, AUC0-∞ and Cmax were (95.6-109.9%), (91.8-106.3%) and (95.2-112.8%), respectively and all were within the bioequivalence acceptance range of 80-125%.These results indicate that 2 tested formulations are bioequivalent and thus could be prescribed interchangeably.
    Full-text · Article · Oct 2012 · Arzneimittel-Forschung
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background: The aim of this study was to determine the bioequivalence of generic (test) and branded (reference) formulations of betamethasone injectable suspension in healthy Iranian subjects for the purpose of meeting regulatory requirements for bioequivalence of the generic formulation in Iran. Methods: 24 healthy Iranian male volunteers were participated for this single-dose, randomized, open label, 2 period crossover study separated by a 2-week washout period. For the assessment of betamethasone, blood samples were obtained before and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 h after drug administration. Plasma concentration of betamethasone was analyzed with a simple, rapid and validated high performance liquid chromatography method with ultraviolet detection. Pharmacokinetic parameters, representing the rate (Cmax, Tmax), and the extent (AUC0-t and AUC0-∞) of betamethasone absorption were calculated and analyzed for 2 formulations. The 2 formulations were to be considered bioequivalent if the 90% confidence intervals (CI)s for the logarithm-transformed values of Cmax, AUC0-t and AUC0-∞ fell within the predetermined range of 80-125%. Results: The 90% CIs of Cmax, AUC0-t and AUC0-∞ were 85.4-104.4%, 96.2-112.1% and 98.3-115.8%, respectively. Conclusion: Based on the 90% CIs of Cmax, AUC0-t and AUC0-∞ in these healthy Iranian male subjects, the test and reference formulations of betamethasone injectable suspension met the regulatory requirements for bioequivalence.
    Full-text · Article · Jun 2013
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Gastric emptying is a complex and extremely variable process. This causes the unpredictability of the bioavailability of drug delivery systems. Gastro retentive drug delivery systems (GRDDS)s have received significant attention in the past decades primarily due to the fact that they can overcome the limitation of conventional oral controlled release drug delivery systems related to fast gastric emptying time. An optimum GRDDS can be defined as a system which remains in the stomach for a sufficient time interval and releases active ingredients in a controlled manner. This, significantly extends the duration of drug release, prolongs dosing interval and increases bioavailability of drugs and therefore improves compliance of the patients and effectiveness of pharmacotherapy. This article gives an overview of the main concepts used to design pharmaceutical dosage forms with prolonged gastric residence times as well as the parameters-affecting gastric emptying, advantages, shortcomings, formulation considerations and, factors that affect gastro retentive systems. The main emphasis is on the entire classification and different types of GRDDSs. Finally evaluation methods of these systems have been summarized.
    Full-text · Dataset · Mar 2014